More on RNXT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (0.0% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/13/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

RenovoRx (NQ:RNXT)
Delayed: 0.88 +0.02 (2.33%)
Prev. Close $0.86  
Open$0.86 
52 Wk High$ 
52 Wk Low$ 
Day High$0.89 
Day Low$0.85 
P/E N/A  
EPS$ 
Volume117,389 

Friends, Peers and Foes (?): CELC, ONCY, OSTX SLS (more...)

Jul 2, 2026 08:30 AM Form 8-K RenovoRx, Inc. For: Jul 01
Jun 30, 2026 05:16 PM Form S-8 RenovoRx, Inc.
Jun 30, 2026 04:55 PM Form 8-K RenovoRx, Inc. For: Jun 30
Jun 24, 2026 05:20 PM Form 4 RenovoRx, Inc. For: Mar 03 Filed by: RYAN UNA S
Jun 11, 2026 08:30 AM RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
Jun 4, 2026 08:30 AM RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
May 28, 2026 08:31 AM RenovoRx receives FDA orphan drug designation for oxaliplatin
May 28, 2026 08:30 AM RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
May 26, 2026 08:32 AM RenovoRx presents pharmacokinetic data at ASCO meeting
May 26, 2026 08:30 AM RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
View All Articles

Entities mentioned with RNXT

View All Entities